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Abstract: Although the literature demonstrates that cardiac autonomic control (CAC) might be
impaired in patients with chronic pulmonary diseases, the interplay between CAC and disease
severity in end-stage lung disease has not been studied yet. We investigated the effects of end-stage
lung disease on CAC through the analysis of heart rate variability (HRV) among patients awaiting
lung transplantation. Forty-nine patients on the waiting list for lung transplantation (LTx; 19 men,
age 38 ± 15 years) and 49 healthy non-smoking controls (HC; 22 men, age 40 ± 16 years) were enrolled
in a case–control study at Policlinico Hospital in Milan, Italy. LTx patients were divided into two
groups, according to disease severity evaluated by the Lung Allocation Score (LAS). To assess CAC,
electrocardiogram (ECG) and respiration were recorded at rest for 10 min in supine position and for
10 min during active standing. Spectral analysis identified low and high frequencies (LF, sympathetic,
and HF, vagal). Symbolic analysis identified three patterns, i.e., 0V% (sympathetic) and 2UV% and
2LV% (vagal). Compared to HCs, LTx patients showed higher markers of sympathetic modulation
and lower markers of vagal modulation. However, more severely affected LTx patients, compared
to less severely affected ones, showed an autonomic profile characterized by loss of sympathetic
modulation and predominant vagal modulation. This pattern can be due to a loss of sympathetic
rhythmic oscillation and a subsequent prevalent respiratory modulation of heart rate in severely
affected patients.
Keywords: heart rate variability; cardiac autonomic control; lung transplantation; spectral analysis;
symbolic analysis; cardiac autonomic dysfunction; autonomic nervous system
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1. Introduction
Lung transplantation (LTx) is a reliable lifesaving option for selected individuals with end-stage
pulmonary disease. Although the number of LTx is increasing over time, the mortality during the
waiting period is still high [1].
One of the possible complications in patients on the waiting list for LTx are cardiovascular events,
which also could impact the mortality rate. Specific hemodynamic factors predict risk in patients
awaiting LTx, suggesting a higher organ allocation priority [1]. However, the factors that impact the
outcome of patients referred for LTx still need to be elucidated [2].
Heart rate variability (HRV) is a reliable and non-invasive tool able to provide information on the
autonomic nervous system control of cardiovascular functions [3]. A reduction of global HRV has been
associated with poor prognosis in several cardiovascular diseases [4]. Although cardiac autonomic
modulation seems impaired in pulmonary diseases [5–7], the interplay between cardiac autonomic
modulation and severity of end-stage pulmonary disorders in patients waiting for LTx has not been
studied yet.
The Lung Allocation Score (LAS) has been developed by the United Network for Organ Sharing
as a tool to allocate donated lungs according to a ‘net benefit’ concept. The LAS estimates each
patient’s medical urgency prior to transplantation and success probability after surgery, in order
to ensure higher priority to patients who could benefit more from lung transplant. The score
ranges from 0 to 100 and is calculated through an algorithm which considers each patient’s disease
diagnosis, physical characteristics, and clinical data. Patients with higher LAS will receive higher
priority for transplant [8]. We used LAS to assess our patient’s disease severity, in terms of ranking
priority, urgency of surgical intervention, and success probability. Our Transplant Center adopted the
Eurotransplant International Foundation LAS Calculator [9].
We formulated the hypothesis that lung disease severity—no matter the disease—may be related
to cardiac modulation markers through HRV analysis. This study aimed at (1) assessing cardiac
autonomic modulation in a population of patients with end-stage lung disease who are candidate for
LTx in comparison with healthy controls and (2) testing the hypothesis that disease severity may be
associated with specific cardiac autonomic markers using two different tools, spectral and symbolic
analysis, for the evaluation of cardiac autonomic modulation.
2. Materials and Methods
2.1. Sample
This was a case–control, prospective study. The protocol was approved by the Internal Review
Board of Ospedale Maggiore Policlinico, Fondazione IRCCS Ca’ Granda, Milan, Italy (protocol number
181, January 2017, 749-2016 bis) and was developed in accordance with the Declaration of Helsinki.
All the subjects signed an informed written consent before study participation.
From January 2017 to June 2018, consecutive adults on LTx waiting list referring to the Lung
Transplant Program of the Policlinico Hospital, Milan, Italy, were enrolled. A cohort of healthy
non-smoking controls were enrolled as well, matched for sex and age with the cases.
The absence of a stable sinus rhythm on electrocardiogram (ECG), percentage of extrasystoles
>5% on ECG, pacemaker rhythm, non-invasive mechanical ventilation, and ongoing exacerbations
(exacerbation of chronic obstructive pulmonary disease, bronchitis, pneumonia) and/or hospitalization
were considered exclusion criteria for this study.
2.2. Experimental Design
All subjects underwent the recoding of ECG and respiration using a thoracic piezoelectric belt in
supine (SUP) position for 10 min and during active standing for 10 min, for a total length of 20 min
of recording per patient. Cardiovascular variables were acquired using an ad hoc telemetric system
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device (BT 16 Plus, Francesco Marazza Elettronica, Monza, Italy). During the recordings, the subjects
were in spontaneous breathing but they were not allowed to talk.
The patients’ respiratory function was also assessed through a 6 minute walking test (6MWT)
to examine their physical capacity status [10]. Spirometric tests were also performed, taking as
satisfactory the highest measurement of forced vital capacity (FVC) and forced expiratory volume in
1 sec (FEV1) [11]. The diffusing capacity of the lung for carbon monoxide (DLCO) was also estimated.
2.3. Lung Disease Severity and Autonomic Modulation
In order to compare autonomic regulation among LTx patients, the LAS was used to assess disease
severity. The median LAS value (33.8) and the 75th percentile LAS value (37.8) were used as thresholds
to categorize patients into three groups: (a) less severe disease (lower than or equal to the median);
(b) severe disease (between 50th and 75th percentile); (c) very severe disease (above the 75th percentile).
Autonomic regulation parameters were compared by linear and non-linear methods of analysis.
2.4. Heart Rate Variability Analysis
The HRV was evaluated through a specific software (Heart Scope II, Amps LLC, New York,
NY, USA) on short samples of 300 beats at rest and orthostatism (ORT) [12]. Every 10 min, a stable
segment of 300 beats associated with stable breathing was selected from the tachogram, whose length
allows for an adequate spectral resolution [13]. To evaluate the autonomic dynamic response to ORT,
we calculated the ∆ORT% ((HRV in SUP position − HRV in ORT position)/HRV in SUP position).
Spectral analysis was performed through the autoregressive model, with a Hanning window and
50% overlap to obtain the spectral power in the low-frequency (LF, frequency band bounded between
0.04 and 0.15 Hz) and high-frequency (HF, frequency band bounded between 0.15 and 0.40 Hz and
synchronous with respiration) components. The model order was estimated for each segment by the
Akaike’s criterion in the present data bounded between 5 to 14 [12]. The LF and HF components can
also be expressed in normalized units (LFnu and HFnu). The normalized components were obtained
by dividing each band power by the total power after subtracting the very low component (<0.04 Hz).
The autonomic balance was calculated as the LF/HF ratio [14].
Nonlinear dynamics were evaluated by symbolic analysis. The R-R dynamics were classified into
3 patterns families: (a) patterns with no variation (0V; all 3 symbols were equal); (b) patterns with
1 variation (1V; 2 consequent symbols were equal, and the remaining symbol was different); and (c)
patterns with 2 variations (2UV or 2LV; all symbols were different from the previous one). The patterns
were expressed as percentages. From a mathematical point of view, the class 1V might be found
but has no significant association with any autonomic tests used to validate the method [15]. The
class 0V is considered a marker of sympathetic modulation, while 2LV and 2UV are markers of vagal
modulation [16].
The relationship between heart frequency and respiration rate was also assessed to compare our
patients. Through cross-spectral analysis, we calculated the squared coherence function (k2) at high
frequencies between the respiratory rate and the heart rate for every patient. RR-RESP HFk2 could
range between 0 (perfect uncorrelation) and 1 (perfect correlation).
2.5. Statistical Analysis
The Shapiro–Wilk test was used to evaluate the normality of the samples. Data are reported as
median and interquartile range (IQR 25%–75%). HRV index comparisons between the groups were
performed by unpaired t-test (p < 0.05) or by Mann–Whitney U test if the data were not normally
distributed. Pearson’s correlation was used to test the relantionship between heart rate, heart rate
variability, and symbolic analysis variables.
GraphPad Prism version 7.0 (GraphPad Software Inc., San Diego, CA, USA) and SigmaPlot 12.0
(Systat Software Inc., San Jose, CA, USA) were used.
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3. Results
3.1. Study Populations
A total of 49 patients on the waiting list for LTx (Group LTx; 30 women; mean (SD) age:
38 ± 15 years) and 49 healthy non-smoking controls (Group HC; 27 women; mean (SD) age:
40 ± 16 years) were examined. Among the LTx Group, 32 patients were diagnosed with cystic
fibrosis, 5 with idiopathic pulmonary fibrosis, 3 with chronic obstructive pulmonary disease, 2 with
nonspecific interstitial pneumonia, 2 with systemic scleroderma, and 5 with other indications for LTx.
Demographic characteristics, cardiovascular risk factors, respiratory function, chronic lung infections,
and medications of patients on the lung transplant list are presented in Table 1. HC had no history of
cardiopulmonary disease and did not take any chronic medication.
Table 1. Demographics, cardiovascular risk factors, respiratory function, chronic lung infections, and
medications of patients on the lung transplant list.
Study Population n = 49
Demographics, n (%)
Age, mean (SD) years 38 (± 15)
Female 30 (61)
Body mass index, mean (SD) 21.8 (± 3.8)
Lung Allocation Score, median (IQR) 33.777 (32.4–37.5)
Cystic fibrosis 32 (65.5)
Idiopathic pulmonary fibrosis 5 (10)
Chronic obstructive pulmonary disease 3 (6)
Nonspecific interstitial pneumonia 2 (4)
Systemic scleroderma 2 (4)
Other indications for lung transplant 5 (10)
Cardiovascular risk factors, n (%)
Hypertension 6 (12)
Diabetes 20 (41)
Pulmonary hypertension 12 (24.5)
mPAP, mean (SD) mmHg 22 (± 5)
Respiratory function, median (IQR)
Exacerbations, n (%) 32 (65.5)
P/F, mean (SD) 305 (± 61)
pCO2, mmHg 42 (38–48)
FEV1 % of predicted 31 (24–49)
FVC % of predicted, mean (SD) 54 (± 16)
FEV1/FVC ratio, mean (SD) 60 (± 21)
DLCO, mean (SD) % 45 (± 22)
6MWT, mean (SD) m 406 (± 169)
Chronic lung infections, n (%)
Burkholderia cepacia 1 (2)
Pseudomonas aeruginosa 27 (55)
MRSA 9 (18.5)
Aspergillus 8 (16.5)
Candida albicans 3 (6)
NTM 3 (6)
Medications, n (%)
Beta-blockers 7 (14.5)
Beta-agonists 37 (75.5)
Anticholinergics 12 (24.5)
Endothelin Receptor Antagonists 1 (2)
Prostanoids 2 (4)
PDE5 inhibitors 1 (2)
Steroids 40 (81.5)
Oxygen 37 (75.5)
n, number; SD, standard deviation; IQR 25–75, interquartile range; mPAP, mean pulmonary arterial pressure; mmHg,
millimeter of mercury; P/F: ratio of arterial oxygen partial pressure to fractional inspired oxygen; FEV1, forced
expiratory volume in 1 s; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide;
6MWT, 6 min walking test; MRSA, methicillin-resistant Staphylococcus aureus; NTM, non-tuberculous Mycobacteria;
PDE-5, phosphodiesterase type 5.
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3.2. Autonomic Evaluation of End-Stage Lung Disease Patients vs. Healthy Controls
LTx patients were characterized by higher HR and, as regards spectral analysis, lower TP, with a
reduction of total heart rate variability (Table 2, column (a)). As to sympatho–vagal balance, LTx patients
showed higher levels of LFnu, higher LF/HF, and lower levels of HFnu than healthy controls. These
data suggest a lower vagal modulation and a higher sympathetic modulation in patients with end-stage
lung disease in comparison to healthy controls. The respiratory rate was significantly coupled with
the HF component of the RR interval, as expressed by RR-RESP HFk2 values (> 0.5) for all groups
(Tables 2 and 3); LTx patients showed higher levels of RESP HF than HC.
Table 2. Comparison of autonomic parameters evaluated by spectral analysis between healthy controls
and patients in supine (a) and orthostatic position (b).
Healthy Controls
n = 49
LTx List Patients
n = 49 p
(a) SUP
Heart rate, median (IQR) bpm 62 (58–71) 88 (79–99) <0.0001
Spectral analysis, median (IQR)
Total power, ms 2 2037 (1114–3706) 533 (180–1051) <0.0001
LFnu 31 (22–43) 64 (36–82) <0.0001
HFnu 66 (53–74) 21 (8–36) <0.0001
LF/HF 0.46 (0.34–0.81) 2.81 (1.30–9.00) <0.0001
RR-RESP HFk 2 0.86 (0.77–0.92) 0.85 (0.50–0.93) 0.26
RESP HF, Hz 0.25 (0.22–0.30) 0.34 (0.26–0.39) <0.0001
(b) ∆ORT
Heart rate, median ∆ORT (IQR) % 22 (9–38) 12 (9–16) <0.0001
Spectral analysis, median ∆ORT (IQR) %
Total power −31 (−56–22) −23 (−56–42) 0.51
LFnu 105 (49–274) 5 (−20–33) <0.0001
HFnu −57 (−77–−39) −1 (−55–50) <0.0001
LF/HF 438 (204–1546) 9 (−60–188) <0.0001
n, number; LTx, transplant list; IQR 25–75, interquartile range; SUP, supine; bpm, beats per minute; ms2, milliseconds2;
LF, low frequency; HF, high frequency; nu, normalized; LF/HF, sympatho–vagal balance; RR, R-R interval; RESP,
respiratory; K2, coherence; Hz, Hertz; ∆, delta; ORT, orthostatism.
Table 3. Autonomic parameters evaluated by spectral analysis of patients on the waiting list for lung
transplant stratified by Lung Allocation Score (LAS). Comparisons between patients with LAS≤ and >
than the median (a) and between patients with LAS≤ and > than the 75th percentile (b).
(a) (b)
LAS ≤Median
n = 25
LAS > Median
n = 24 p
LAS ≤ 75th p.
n = 37
LAS > 75th p.
n = 12 p
Heart rate, mean (SD) bpm 87 (± 18) 87 (± 15) 0.97 86 (± 17) 88 (± 12) 0.79
Spectral analysis, median
(IQR)
Total power, ms 2 597 (232–1091) 331 (150–928) 0.43 551 (206–1080) 439 (164–841) 0.72
LFnu 75 (50–85) 55 (28–69) 0.04 68 (52–85) 41 (22–62) 0.005
HFnu 14 (7–34) 25 (8–37) 0.36 14 (7–36) 25 (13–46) 0.37
LF/HF 5.98 (1.53–10.89) 2.24 (1.09–4.29) 0.17 4.13 (1.56–10.92) 1.70 (0.63–3.47) 0.04
RR-RESP HFk 2 0.73 (0.35–0.89) 0.90 (0.63–0.94) 0.11 0.80 (0.41–0.92) 0.91 (0.64–0.94) 0.35
RESP HF, Hz 0.35 (0.25–0.44) 0.34 (0.28–0.37) 0.67 0.35 (0.25–0.40) 0.34 (0.29–0.36) 0.91
n, number; p., percentile; IQR 25–75, interquartile range; bpm, beats per minute; ms2, milliseconds2; LF, low
frequency; HF, high frequency; nu, normalized; LF/HF, sympatho–vagal balance; RR, R-R interval; RESP, respiratory;
K2, coherence; Hz, Hertz.
Symbolic analysis revealed higher levels of 0V% (23 (12–35) vs. 16 (11–27), p = 0.02), a marker
of sympathetic modulation, and lower levels of 2LV% (7 (4–13) vs. 11 (8–18), p = 0.005), a marker of
vagal modulation, in comparison to healthy controls (Figure 1). These observations are consistent
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with the previous ones, confirming a higher sympathetic modulation and a lower vagal modulation in
patients with end-stage lung disease. In the present study, patient’s average heart rate and 2UV were
negatively correlated in supine position, as the faster the HR, the lower the 2UV (r = −0.29, p = 0.04),
and negative correlation was observed also with HF spectral power (r = −0.30, p = 0.03), suggesting
less variability and lower vagal modulation of the heart explored in the time domain, spectral analysis,
and symbolic analysis.
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Figure 1. Comparison of autonomic parameters evaluated by symbolic analysis between healthy
controls (HC, n = 49) and p tients on the w iting list for lung transplant (LTx, = 49) in supine position;
*, statistically significant.
3.3. Autonomic Evaluation Among End-Stage Lung Disease Patients According to Disease Severity
The results of the spectral analysis are reported in Table 3, column (a). Patients with a LAS lower
than or equal to the median LAS showed higher LFnu than patients with a LAS above the median. No
other significant differences were found in HR and at spectral decomposition when comparing these
two groups of patients.
When performing a symbolic analysis (Figure 2), a difference was found between the two groups:
more severely affected patients had significantly lower levels of 0V% (20 ± 16 vs. 31 ± 15, p = 0.01) and
higher levels of 2LV% (10 (7–18) vs. 5 (3–8), p = 0.004).
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These data suggest a lower sympathetic modulation and a predominant vagal modulation in
more severely affected patients.
3.4. Comparison Above and Below the 75th Percentile LAS
The results of the spectral analysis are reported in Table 3, column (b). Spectral decomposition
revealed lower levels of LFnu for patients with a LAS above the 75th percentile in comparison with
patients with a LAS lower than or equal to the 75th percentile. More severely affected patients also
showed a lower LF/HF ratio in comparison with less severely affected ones. No other significant
differences were found in HR and at spectral decomposition.
Again, symbolic analysis (Figure 3) showed a difference between the two groups: more severely
affected patients had lower levels of 0V% (15 (±13) vs. 29 (±15), p = 0.006) and significantly higher
levels of 2LV% (11 (7–19) vs. 6 (3–11), p = 0.023) and 2UV% (26 (12–37) vs. 18 (10–23), p = 0.04). These
data confirmed a lower sympathetic modulation and a predominant vagal modulation in more severely
affected patients.
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Figure 3. Co parison of autono ic para eters evaluated by symbolic analysis between patients on
the lung transplant list with a LAS lower than or equal to the 75th percentile (n = 37) and patients on
the transplant list with a LAS above the 75th percentile (n = 12); *, statistically significant.
3.5. Cardiac Autonomic Control during the Active Standing Test
We also assessed the autonomic dynamic response to ORT by comparing healthy controls and
patients waiting for LTx. The ∆ORT% of both spectral and symbolic parameters were compared;
the results are reported in Table 2, column (b).
LTx patients showed a significantly lower ∆ORT% in HR, LFnu, HFnu, and LF/HF, revealing a
reduced variation of autonomic modulation with the active standing test in comparison to HC and a
different sympatho–vagal balance. The results of the symbolic analysis also showed stronger variations
in 0V% (marker of sympathetic modulation) and in 2UV% (marker of vagal modulation) in healthy
controls than in patients with end-stage lung disease (∆ORT% 0V%: 97 (30–244) vs. 38 (−6–105),
p = 0.014; ∆ORT% 2UV%: −58 (−72–−16) vs. −18 (−47–28), p = 0.001).
4. Discussion
The major findings of the present study are: (1) Patients with end-stage lung disease have an
autonomic imbalance in the direction of higher sympathetic and lower vagal modulation of the heart
at rest and blunted cardiac autonomic responses to orthostatic stress when compared with a healthy
control group; (2) Patients with more severe lung disease assessed by LAS showed an autonomic
profile characterized by a prevalent cardiac vagal respiratory modulation and a loss of sympathetic
efference compared to less severe lung disease patients.
Patients with cardiac autonomic dysfunction present several associated lung diseases, such as
chronic obstructive pulmonary disease (COPD) [6,7], pulmonary arterial hypertension (PAH) [17],
and cystic fibrosis (CF) [18] compared to age-matched controls. Although global HRV is reduced in
patients with several lung diseases compared to healthy controls, the sympatho–vagal balance may
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be different considering disease severity and respiratory function [5,6]. The results of the current
study indicate that in patients with end-stage lung disease there is a prominent reduction in cardiac
autonomic modulation in the direction of vagal control and an increase in sympathetic modulation in
comparison to age- and sex- matched healthy individuals.
Airflow obstruction levels in COPD increase the risk of ventricular arrhythmia and are associated
with worse linear and non-linear heart rate dynamics [6]. Impaired HRV responses are associated
with disease severity, although diverse pathophysiological manifestations may be present due to the
complexity of COPD as a disorder [6,7]. For instance, a worse oxygenation status in COPD patients is
associated with higher cardiac vagal and lower cardiac sympathetic outputs. Although there is no direct
relation with the degree of airway narrowing in cardiac autonomic modulation, chronic hypoxemia can
increase cardiac vagal activity and depress the sympathetic modulation of COPD patients [7]. Recently,
a similar cardiac autonomic profile was reported in patients with community-acquired pneumonia
(CAP) [5]. The global contribution from cardiac autonomic control, represented by the total power
index of HRV spectral analysis, was reduced in CAP patients in comparison with healthy controls.
Symbolic analysis showed that vagal-mediated HRV was higher and the sympathetic rhythmical
component was reduced in CAP patients compared to healthy controls. Also, HRV sympathetic
oscillations were particularly reduced in more severely affected patients, i.e., patients with a time to
clinical stability >7 days, compared to less severely affected patients (time to clinical stability ≤7 days).
The current study demonstrated that patients with more severe end-stage lung disease (as measured
by LAS) had an autonomic profile characterized by a predominant respiratory vagal modulation and
a loss of sympathetic rhythmic oscillation. Furthermore, patients with more-advanced-stage lung
disease showed a global reduction of HRV, with a loss of sympathetic oscillatory heart rhythmicity,
while maintaining vagal respiratory modulation. On the other hand, in less severe stages of the disease,
sympathetic modulation prevailed in response to a series of pathological mechanisms (such as hypoxia).
Taken together, these are the potential underlying mechanisms to explain the HRV relationships with
lung disease severity in end-stage lung disease patients.
According to previous studies, pulmonary hemodynamics are a predictor of mortality among
patients awaiting LTx. For instance, patients on the LTx waiting list who have increased pulmonary
vascular resistance (PVR) and a lower force vital capacity (FVC %) should be considered for a higher
organ allocation priority [1]. We suggest that cardiac autonomic control (CAC) assessed by HRV could
provide new insights into pulmonary hemodynamics regarding cardiovascular risk and higher organ
allocation priority in patients awaiting LTx.
For example, in PAH, sympathetic overactivity is evidenced in some studies by increased systemic
vascular resistance [19] or direct measurement of muscle sympathetic nervous activity, and chronic
overactivity could relate to disease severity [20,21]. However, HRV studies revealed that, regarding the
autonomic modulation of the heart, both sympathetic and vagal branches are impaired in PAH
patients compared to healthy controls [17,21,22]. The incoherence of increased muscle sympathetic
nerve activity and decrease in both vagal- and sympathetic-mediated HRV indexes is not completely
explained yet. However, a reasonable underlying mechanism maybe similar to the one previously
reported for heart failure, where the LF power of the HRV spectral analysis seems related to a reduced
susceptibility to respond to changes in sympathetic tone [23,24]. Thus, the reduction in LF power in
PAH patients may result from chronic sympathetic activation, as has been reported previously [21].
Most of the patients (65%) included in the current study had CF. This complex disease affects
many organs, but the associated autonomic nervous system regulations have not yet been widely
studied [18]. Although autonomic nervous system disruption may contribute to CF pathogenesis,
there is little knowledge of the cardiac autonomic profile of CF patients. To our knowledge, there
is a single study that investigated the cardiac autonomic profile in adults with CF, which did not
find any differences in HRV markers between CF patients and healthy controls. However, in the CF
group, FEV1 values (as percentage of predicted values) were positively associated with the cardiac
sympatho–vagal balance (LF/HF) [25]. This may be explained by a physiological afferent vagal nerve
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activation with larger inspiratory tidal volumes related to pulmonary disease progression. In children
with CF, a predominance of cardiac sympathetic modulation to vagal modulation was found in
comparison with age-matched healthy controls [26]. Neither Szollosi et al. [25] nor Florêncio et al. [26]
investigated patients with age, clinical features, or disease severity similar to those of the patients in
our study, which complicates comparisons with our findings.
The predominance of CF in our case study is mainly due to the specialization of our Transplant
Center. We considered the hypothesis of a bias of our study towards CF. We conducted analyses on
subgroups comparing CAC and respiratory characteristics of patients affected by CF or diagnosed
with other pathologies. We included comparisons between both whole groups and LAS-restricted
sub-groups, but we did not find any difference (see Supplementary Materials, Tables S1, S2 and S3
for sub-groups analyses). Thus, we could speculate that the results are not related to the underlying
disease. However, on this topic a cautious approach should be adopted, and we cannot rule out the
existence of different autonomic patterns in end-stage lung diseases of different origins.
HRV markers at rest provide relevant information regarding cardiac autonomic modulation.
However, the vagal and sympathetic contributions to cardiac regulation could be highlighted by the
HRV response to an autonomic stimulus, such as active standing test (orthostatic stress) [14,16,27].
The results of the current study indicate that the sympathetic- and vagal-mediated HRV responses
(∆LF and ∆HF, respectively) to ORT stress are blunted in end-stage lung disease patients in comparison
to healthy controls. Recently, moderate to severe COPD patients showed an impaired HRV response to
orthostatic stress and breathing maneuver, which was not present in less severely affected patients [6].
Although the HRV response to active standing test has been useful to add novel information regarding
the association between cardiac autonomic regulation and cardiovascular outcomes in some disease
conditions [16,27], the role of HRV analysis in relation to autonomic maneuvers must be further
elucidated in patients with pulmonary disease.
In interpreting our results, some limitations must be taken into account. First, 49 patients and 49
healthy controls were included in this study; although our sample is sizable compared to other studies
in this research area, further developments and more significant data could be achieved through an
expansion of the sample size. Second, as we previously explained, the Lung Allocation Score was not
implemented to provide a direct measure of disease severity: it has been developed to assess patients’
medical urgency, need for surgery, and survival probability after transplantation, and with this mind,
we used it also to assess illness severity. Third, the population had a prevalence of cystic fibrosis
and, although we conducted promising sub-groups analysis, this must be considered a limitation
when interpreting our results. Finally, we did not exclude patients on different medications such
as anticholinergics, beta blockers, and beta-agonists, which could affect cardiac autonomic control.
However, this study aimed to characterize patients with end-stage lung disease in real-life conditions,
and we know very well that many patients in these conditions are on medications affecting HRV.
This element must be considered a limitation when interpreting the study results.
5. Conclusions
End-stage lung disease patients awaiting lung transplantation show higher sympathetic- and
lower vagal-mediated HRV at rest and blunted HRV responses for both vagal and sympathetic indexes
to orthostatic stress compared to age-matched healthy controls.
Furthermore, a prevalence of cardiac vagal modulation compared to sympathetic modulation is
present in more severe lung disease patients compared to less severe lung disease patients, as assessed
by the Lung Allocation Score.
From the clinical point of view, these results could be used by clinicians for a better stratification of
LTx patients, considering that more severely affected patients have an autonomic profile characterized
by loss of sympathetic modulation and predominant vagal modulation, which could be related to a
worse prognosis. These data, if confirmed on a larger population, will help clinicians better stratify
patients and identify those at high risk.
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